Navigation Links
Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
Date:11/1/2007

ure plans, events or performances are forward-looking statements. Any statement containing words such as "believes," "anticipates," "plans," or "expects," and other statements which are not historical facts contained in this release are forward-looking, and these statements involve risks and uncertainties and are based on current expectations. Consequently, actual results could differ materially from the expectations expressed in these forward-looking statements. Particularly, but without limitation, the above statements regarding the expected impact of the restatements and the expected timing of our filings constitute forward.looking statements that are based on our current expectations. The final amounts and the detailed presentation of the restatements will be included in our upcoming filings after we have completed our work on the restatements, our independent auditors have completed their review of the restatements, and the Audit Committee has completed its final review of the restatements. There can be no assurance that this information will not change, possibly materially, before we file the restated financial statements. Because these forward.looking statements involve risks and uncertainties, there are important factors that could cause our actual results, as well as our expectations regarding materiality or significance, to differ materially from those in the forward.looking statements. These factors include the risk that the preparation of our restated financial statements or other subsequent events may require us to make additional adjustments. Furthermore, as noted above, there can be no assurance that additional issues or matters will not arise from the Amex investigation or the related audit, which is ongoing. For a discussion of a variety of risk factors affecting our business and prospects, see "Risk Factors" in our Annual Report on Form 10.KSB for the year ended December 31, 2006 and our subsequent filings with the Securities and Exchange Commissio
'/>"/>
SOURCE Z Trim Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...rk for ER patients with hypoxia remains unclear , ...ing to the world,s most elevated natural laborator...hat the established medical rules about the amount...wrong. , "Some people can tolerate extremely low l...d Dr. Michael P.W. Grocott, from University Colleg...
(Date:1/7/2009)...nt Increase in Patients Unable to Pay Out-of-Pocke...iting Hospital ERs , , SACRAMENTO, Calif., Jan. 7... having a dramatic impact on California,s communit... report by the California Hospital Association (CH...onducted in November 2008 among hospital chief fin...
(Date:1/7/2009)...t failure, slowed cell growth, study says , ... a drug used for many years to treat irregular hea...-fighting agent, researchers report. , Cancer cell... many of these cells are oxygen-deprived and need ...ypoxia-inducible factor (HIF-1), which help cells ...
(Date:1/7/2009)...le at Albertsons stores throughout AR, AZ, CO, FL,...n,s LLC announced an expansion of its Albertsons ...y by introducing a new offering of $10.99 for a 90...n, Albertsons has added new generic medications to...covered by this discount program. Additional medi...
Breaking Medicine News(10 mins):Health News:Study of Everest Climbers Questions Oxygen Use 2Health News:Study of Everest Climbers Questions Oxygen Use 3Health News:Economic Downturn Takes Toll on California Hospitals 2Health News:Heart Drug May Be a Cancer Fighter 2Health News:Albertson's LLC Launches $10.99 for 90-day Supply of Generic Drugs as Part of Rx-tra Savings Prescription Discount Program 2
...cientists have reported a breakthrough, towards th...eclampsia.// The researchers from the US National...lampsia had high levels of two proteins several mo...Reporting their findings they explained that the t...
...uicide is the third leading cause of death in Cana...It is also a prevalent problem within Aboriginal c...proaching on September 10, 2006, two experts from ... are available to comment on the health challenges...
...he U.N. children's agency, UNICEF and the Barcelon... the team has agreed to donate $1.9 million a year...leged children with AIDS in developing countries. ...ds the AIDS programs in Swaziland, a poverty stric...
...hikungunya has re-emerged in the country after a p...Maharashtra, Andhra, Tamil Nadu and Kerala. Recent...hikungunya fever. Mosquitoes are the carriers who...o human. The National Institute of Communicable D...
Other Medicine News:Health News:Placental Proteins Could Be Responsible For Pre-eclampsia 2Health News:Getting Serious About Suicide Prevention 2
(Date:1/7/2009)...-- ImQuest Life Sciences announced today the succe... and Drug Administration to initiate human clinica...tor IQP-0410. ImQuest anticipates initiating their...-0410 is a novel small molecule inhibitor of HIV w...nscriptase inhibitor (NNRTI). The compound possess...
(Date:1/6/2009)...s from prior U.S., U.K. and China Trials , , SA...nc. (VTI), a development stage company targeting l...as begun for a randomized, controlled, multi-cente...acorporeal Liver Assist Device (ELAD) as a treatme...er three protocols. The study is open for enrollme...
(Date:1/6/2009)...SNewswire/ -- Sequella, Inc., a clinical-stage bio...emic potential, announced today that SQ109, its le...s (TB), was the first drug approved for evaluation...ynport Vaccine Company LLC and Quintiles Transnati...ute of Allergy and Infectious Diseases (NIAID), Na...
(Date:1/5/2009)...lene Pharmaceuticals announced today that it has i...protein kinase inhibitor, CX-4945, in patients wit...ultiple myeloma. The primary endpoints of the oral..., tolerance and PK properties of CX-4945 and to se...addition, multiple mechanism-related pharmacodynam...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 1National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 2National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 1Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 2Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 4Rutgers research partner Stemcyte Inc expands to New Jersey 18164 1Rutgers research partner Stemcyte Inc expands to New Jersey 18164 2Go Speed Racer 21 Revving up the worlds fastest nanomotors 18161 1
...S WIRE)--May 14, 2007 - Oculus Innovative,Sciences...cyn,Technology was the subject of a poster present... (EWMA) conference that was held in,Glasgow, Scotl... Results About an Antimicrobial,Solution in the Tr...ng & Harding infection criteria to evaluate th...
...-May 15, 2007 - Gemin X Biotechnologies,Inc. annou...Blood,demonstrated that its lead compound, obatocl...le Cell Lymphoma (MCL) cell lines and,primary cell...small,molecule specifically designed to inhibit al...validated cancer target, thus restoring,the natura...
Other Medicine Technology:Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 2Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 3Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
... Rheumatoid Factor IgM enzyme linked immunosorbent...(RF IgM). Enzyme-linked immunosorbent assay method...M Rheumatoid Factor in human serum. The results of...gnosis of Rheumatoid Arthritis when supported by o...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)
...r is a high precision optical system for corneal t...terior eye segment, based on a Revolving Dual Chan...GALILEI combines the advantages of two technologie...re data, while Scheimpflug imaging is optimal for ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w
Medicine Products: